{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019433","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.277284+00:00","generated_at":"2026-06-01T23:10:16.881369+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Evofem Q1 net sales down 38% to $3.6M; loss narrows; Aditxt merger progress","bullets":["Net sales $3.6M vs $5.8M a year ago, attributed to WAC increase cycle and Change Healthcare cyberattack.","Loss from operations narrowed 21% to $2.8M; total operating expenses decreased 31% to $6.4M.","Received $1M from Aditxt in May; Aditxt to invest additional $2.5M by July 1, 2024; merger expected H2 2024.","USPTO allowed new Phexxi composition-of-matter patent; fifth U.S. patent covering the drug.","Medi-Cal rebate reduced 7.4% effective July 1, 2024, improving net pricing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019433","json":"https://secwatch.observer/filing/0001493152-24-019433.json","markdown":"https://secwatch.observer/filing/0001493152-24-019433.md","text":"https://secwatch.observer/filing/0001493152-24-019433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224019433/0001493152-24-019433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224019433/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:10:16.881369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"332a602499acc8829166935b0cdc33acd899c265","claim":"Evofem Biosciences, Inc. reported the three months ended March 31, 2024 results: revenue $3.6 million, net income loss from operations improved to $2.8 million.","evidence_excerpt":"15.4 million beneficiaries. Effective July 1, 2024, Evofem will pay a 7.4% lower rebate to Medi-Cal on Phexxi prescriptions dispensed to its beneficiaries. ● Net sales were $3.6 million for the first quarter of 2024, reflecting anticipated cyclical softness following the wholesale acquisition cost (WAC) increase on January 1, 2024, and the impact of the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224019433/0001493152-24-019433-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$3.6 million"},{"label":"Net income","value":"loss from operations improved to $2.8 million"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}